GENE ONLINE|News &
Opinion
Blog

BCMA
Partnerships CAR T-cell Therapy
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
2022-12-12
Trials & Approvals Cell Therapy
J&J, Legend’s Cell Therapy Gets FDA Nod
2022-03-01
Trials & Approvals Bristol Myers Squibb
Bristol-Myers Squibb’s Abecma Becomes First Approved CAR T-Cell Therapy for Multiple Myeloma in Japan
2022-01-24
M&A Multiple Myeloma
AbbVie to Acquire TeneoOne and Its Lead Multiple Myeloma Drug
2021-06-27
Trials & Approvals
BMS, bluebird’s Multiple Myeloma Drug Becomes First BCMA Targeting CAR-T Therapy to Snag FDA Okay
2021-03-28
Trials & Approvals Multiple Myeloma
GSK’s anti-BCMA Therapy Notches FDA Approval for Refractory Multiple Myeloma
2020-08-09
Licensing Multiple Myeloma
Kite Pharma Licences Teneobio’s Antibody Platform to Fight Multiple Myeloma
2020-04-03
IPO Acute Lymphoblastic Leukemia
Tracking “OFF THE SHELF” CAR-T Cell therapy & an IPO worth $100M
2018-10-15
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top